Eciruciclib

N/A

Report date: 2025/07/29 17:52:27
NME

Base Information

Drug NameEciruciclib
Drug Alias NameBPI-1178
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeta Pharma Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNational Cancer Center ChinaBeta Pharma (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A